Wenlong Li

In October 2016, I joined the group of Alfred H. Schinkel as a PhD student. My project aims to understand the impact of ABC drug efflux transporters, CYP3A and carboxylesterase drug-metabolizing enzymes on in vivo pharmacology, toxicology and physiology, as well as resistance and susceptibility of tumors to anticancer pharmacotherapy by using genetically modified mouse models. Application of the insights and model systems obtained is used to improve pharmacotherapy of cancer and many other diseases, and to reduce toxicity and carcinogenesis risks.